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A B S T R A C T   
Aim: To obtain a quantitative expression profile of the main genes involved in the cAMP-signaling cascade in 
human control atria and in different cardiac pathologies. 
Methods and results: Expression of 48 target genes playing a relevant role in the cAMP-signaling cascade was 
assessed by RT-qPCR. 113 samples were obtained from right atrial appendages (RAA) of patients in sinus rhythm 
(SR) with or without atrium dilation, paroxysmal atrial fibrillation (AF), persistent AF or heart failure (HF); and 
left atrial appendages (LAA) from patients in SR or with AF. Our results show that right and left atrial appendages 
in donor hearts or from SR patients have similar expression values except for AC7 and PDE2A. Despite the 
enormous chamber-dependent variability in the gene-expression changes between pathologies, several distin-
guishable patterns could be identified. PDE8A, PI3Kγ and EPAC2 were upregulated in AF. Different phospho-
diesterase (PDE) families showed specific pathology-dependent changes. 
Conclusion: By comparing mRNA-expression patterns of the cAMP-signaling cascade related genes in right and 
left atrial appendages of human hearts and across different pathologies, we show that 1) gene expression is not 
significantly affected by cardioplegic solution content, 2) it is appropriate to use SR atrial samples as controls, 
and 3) many genes in the cAMP-signaling cascade are affected in AF and HF but only few of them appear to be 
chamber (right or left) specific. 
Topic: Genetic changes in human diseased atria. 
Translational perspective: The cyclic AMP signaling pathway is important for atrial function. However, expression 
patterns of the genes involved in the atria of healthy and diseased hearts are still unclear. We give here a general 
overview of how different pathologies affect the expression of key genes in the cAMP signaling pathway in 
human right and left atria appendages. Our study may help identifying new genes of interest as potential 
therapeutic targets or clinical biomarkers for these pathologies and could serve as a guide in future gene therapy 
studies.   
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E-mail address: rodolphe.fischmeister@inserm.fr (R. Fischmeister).   
1 These authors contributed equally. 
Contents lists available at ScienceDirect 
Journal of Molecular and Cellular Cardiology 
journal homepage: www.elsevier.com/locate/yjmcc 
https://doi.org/10.1016/j.yjmcc.2021.02.006 
Received 5 January 2021; Received in revised form 4 February 2021; Accepted 11 February 2021   
Journal of Molecular and Cellular Cardiology 155 (2021) 10–20
11
1. Introduction 
The β-adrenergic receptor (β-AR)/cyclic adenosine monophosphate 
(cAMP) pathway is a major pathway involved in the sympathetic 
regulation of heart function. It regulates cardiac contractility, relaxation 
and heart rate. β-AR activation by noradrenaline or adrenaline triggers a 
sequence of signaling events which starts by G-protein activation, 
stimulation of different adenylyl cyclase (AC) isoforms which synthetize 
cAMP leading to protein-kinase-A (PKA) mediated phosphorylation of 
several key proteins involved in excitation-contraction (EC) coupling, 
such as L-type Ca2+ channels (LTCC), phospholamban (PLB), ryanodine 
receptors type-2 (RyR2) and troponin-I (TnI) [1]. A-kinase anchoring 
proteins (AKAPs) bind PKA [2] and phosphatases (PP2 and PP1), which 
act as signaling scaffolds to promote phosphorylation of target proteins. 
cAMP has also PKA-independent targets in the heart, such as channels 
for cyclic nucleotides transport across the membranes (MRP) [3–5] or 
the small G-protein exchange-factor Epac (Exchange Protein directly 
Activated by cAMP) [6] involved in hypertrophic growth [7,8], which in 
turn activates calcium/calmodulin-dependent kinase type-IIδ 
(CaMKIIδ). The levels of cAMP and thus the degree of PKA and Epac 
activation are finely regulated by cyclic nucleotide phosphodiesterases 
(PDEs). There are 5 families (PDE1-4 and PDE8) of cardiac PDEs 
degrading cAMP [9]. Other proteins also play an important role in EC 
coupling by modulating β-AR desensitization (β-arrestins) or activating 
phosphorylation after an intracellular calcium increase (CaMKIIδ) 
(Fig. 5). 
One important question is whether differences in neurohumoral 
regulation between right and left heart chambers are limited to elec-
trophysiological and phenotypic features [10–12] or extend to genetics, 
and how it can differentially affect left and right atria. During the last 
years, many publications have highlighted the importance to study ge-
netic differences between cardiac cavities. Phillips and colleagues [13] 
reported no difference in the expression level of more than 600 proteins 
between the RV and the LV from pig and rabbit including contractile/ 
structural proteins and oxidative phosphorylation components. No 
plasma membrane voltage-gated ion channel was analyzed, but a few 
major Ca2+ handling proteins (SERCA2, RyR2) and signal transduction 
components (Ca2+/CaMKIIδ, PKA type-I and type-II) showed no varia-
tion in their expression level [13]. A recent single-cell resolution anal-
ysis also showed similar nuclear transcriptional patterns when 
comparing right versus left atria from dead donors non-failing patients 
[14]. However, only limited information about β-AR/cAMP pathway 
genes and their expression in human healthy and diseased atria is 
available. 
Several electrophysiological studies have shown the importance of 
the β-AR/cAMP pathway in the development and maintenance of many 
cardiovascular diseases such as heart failure (HF) and atrial fibrillation 
(AF). However, the relationship between electrophysiological changes 
in cellular signaling and changes in β-AR/cAMP pathway regulatory 
genes has mainly been investigated for individual targets in specific 
diseases and heart regions. 
Unbiased genetic studies in the human heart considering both 
interchamber differences and pathological re-modeling are extremely 
important to characterize new potential therapeutic targets before 
bringing them into deeper mechanistic and translational studies as well 
as to better understand adaptation or maladaptation during disease. 
Recently, gene therapy technology has begun to be tested to treat ven-
tricular pathologies. However, expression of the tested genes and their 
disease driven changes have not always been studied in the human tis-
sues, or only in a very small number of samples with variable reference 
genes, leading to contradictory results. Here, we aimed to study gene 
expression changes that occur in the human atrium with various pa-
thologies at right and left chambers in order to gain a general under-
standing of the remodeling of the β-AR/cAMP pathway promoted by 
different pathologies. We studied the expression of 48 target mRNAs in 
113 appendage tissue samples from control donor patients, patients 
being in sinus rhythm (SR) with or without atrial dilation, having 
different forms of AF, or suffering from HF. Our data reveal that many 
genes involved in the β-AR/cAMP pathway are affected in AF and HF but 
only few changes are right or left atrial specific. 
2. Methods 
2.1. Human atrial-tissue samples 
A total of 113 human atrial appendage-tissue samples were collected 
from a total of 97 patients undergoing open-heart surgery either at the 
Institut Hospitalier Jacques Cartier, Massy, France, at the Cardiac Sur-
gery Department, Hospital de la Santa Creu i Sant Pau/Universitat 
Autònoma de Barcelona, Spain, at the Cardiology and Pneumology 
Department, Georg-August-Universität Göttingen, Germany, at the 
Cardiac Surgery Department, University Hospital Essen, Germany, at the 
University Medical Center Hamburg-Eppendorf, Germany, or at the 
Department of Pharmacology and Pharmacotherapy, University of 
Szeged, Hungary. 81 specimens of right (RAA) and left (LAA) atrial 
appendage tissues were obtained from 80 patients in sinus rhythm with 
(SRd) or without (SRnd) atrial dilation, or with paroxysmal atrial 
fibrillation (pAF) or long-standing persistent atrial fibrillation (cAF), 
subjected to atrial cannulation for extracorporeal circulation. 32 right 
and left atrial appendage tissues were collected from 8 control donors 
(Ctl) and 9 end-stage heart failure dilated atria (HF) from explanted 
human hearts, respectively, at the time of the transplantation. All sam-
ples were frozen in liquid nitrogen and stored at − 80 ◦C. Adipose tissue 
was removed before the cryopreservation of the sample. The study was 
conducted in accordance with the Declaration of Helsinki principles, and 
approved by the Ethical Committees of all included institutions. 
Informed consent was obtained from each patient. Details regarding the 
clinical characteristics of the patients and their medication are shown in 
Tables 1 and 2. 
2.2. RNA isolation and cDNA synthesis 
76 snap-frozen tissue samples were weighed and placed in pre- 
cooled tubes containing TRIzol® reagent (Invitrogen, Life Technolo-
gies, France) and rapidly subjected to automated grinding in a Bertin 
Precellys 24 (Bertin Technologies, France). Total RNA extraction was 
carried out using standard procedure according to the manufacturer’s 
instructions. RNA concentration and purity were evaluated by optical 
density (Biophotometer, Eppendorf, BioServ, France) and the integrity 
of the RNA samples were analyzed on a Bioanalyzer 2100 with the 
RNA6000 Nano Labchip Kit (Agilent Technologies, Santa Clara, CA, 
USA). The RNA-integrity number (RIN) was calculated by the instru-
ment software. First strand cDNA synthesis was performed from 1-μg of 
total RNA with random primers and MultiScribeTM Reverse Transcrip-
tase according to the provided protocol (Applied Biosystems, Life 
Technologies, France). To minimize intergroup variations, samples of 
each experimental group were processed simultaneously. 
Total RNA content, 260 nm/280 nm optical-density (OD) ratio and 
RNA-integrity number (RIN) values were obtained from right and left 
atrial appendages without or with pathological conditions. RIN values 
were ranged between 5.5 and 8.5, with a mean value of 6.5 ± 0.3 for 
RAA SRnd, 7.0 ± 0.2 for RAA SRd, 6.4 ± 0.3 for RAA pAF, 6.6 ± 0.1 for 
RAA cAF, 7.5 ± 0.6 for LAA SR, 6.5 ± 0.3 for LAA AF, 6.9 ± 0.4 for RAA 
Ctl, 7.0 ± 0.4 for LAA Ctl, 7.0 ± 0.5 for RAA HF and 7.1 ± 0.3 for LAA 
HF. There were no differences in RNA content between the groups. The 
quality control parameters for human total RNA samples were similar 
regardless of human tissue-sample collection, with no difference be-
tween the groups. 
2.3. Real-time qPCR and quantification 
Real-time PCR assays were performed using TaqMan® 384-well 
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microfluidic card technology from Applied Biosystems (TaqMan® Array 
Card or TAC, Life Technologies, France) and the TaqMan® Human 
Endogenous Control Panel. These TAC were designed to study the 
expression of 48 target genes: ABCC4 (MRP4), ABCC5 (MRP5), ADCY2 
(AC2), ADCY4 (AC4), ADCY5 (AC5), ADCY6 (AC6), ADCY7 (AC7), 
ADCY9 (AC9), AKAP5, AKAP6, AKAP7, AKAP9, AKAP13, ARRB1 
(Arrestin b1), ARRB2 (Arrestin b2), AURKAIP1 (AKIP), CAMK2D (CaM-
KIID), NPPA (ANP), NPPB (BNP), PDE1A, PDE1C, PDE2A, PDE3A, 
PDE3B, PDE4A, PDE4B, PDE4D, PDE8A, PIK3CG (PI3Kγ), PKIA, PKIB, 
PPP1CA (PP1A), PPP1R1A (IPP1), PPP1R2 (IPP2), PPP2CA (PP2CA), 
PRKACA (PKACA), PRKACB (PKACB), PRKAR1A (RIA), PRKAR2A 
(RIIA), PRKAR2B (RIIB), RAPGEF3 (EPAC1), RAPGEF4 (EPAC2)), 
ADRB1 (β1-AR), ADRB2 (β2-AR), GNAI1 (Gi1), GNAI2 (Gi2), GNAI3 
(Gi3), GNAS (Gs) (Supplemental Table 1) relative to 5 reference genes 
(POLR2A, YWHAZ, GAPDH, IPO8, PPIA) recently validated for a study 
using right and left cardiac cavities from different human tissue cohorts 
[15]. Each PCR reaction was performed on 4-ng of cDNA in a volume of 
1-μl. The thermal cycling conditions for PCR amplification on TAC were 
10-min at 94.5 ◦C, followed by 40 cycles of 30-s at 97 ◦C and 1 min at 
59.7 ◦C, on an ABI-Prism 7900HT Sequence Detection Instrument 
(Applied Biosystems, Life Technologies, France). Each TaqMan® assay 
was previously validated by Applied Biosystems and the efficiency of 
amplification was certified to be superior to 90% by the supplier. For 
each group, an average Ct value was calculated. The determination of 
the relative gene-expression ratio was achieved using the ΔΔCt method 
and normalized by the geometric mean of a set of stable housekeeping 
genes. 
2.4. Western blot analysis 
37 snap frozen human atrial appendage-tissue samples were ho-
mogenized in RIPA lysis buffer (NaCl 150 mM, Triton 1%, SDS 0.1%, 
SOD 0.5%, Tris 50 mM, Protease- and Phosphatase-Inhibitor Cocktail 
(Roche)) using a homogenisator (MICCRA D-1). After three homogeni-
zation steps for 20 s each, always followed by cooling of the samples in 
liquid nitrogen, samples were incubated on ice for 1-h. After centrifu-
gation (12,000 rpm, 5-min, 4 ◦C) supernatants were stored at − 20 ◦C 
until usage. Protein quantification was performed using BCA Protein 
Assay (Pierce BCA Protein Assay Kit, Thermo Scientific, #23227) and 
50-μg of total protein were loaded on 8% SDS gels for SDS poly-
acrylamide gel electrophoresis. Then, proteins were transferred to 
nitrocellulose membrane (Amersham, #106000 02) using a tank blot 
system. For immunoblot analysis, the following antibodies were used: 
PDE2A (Fabgennix 101AP, rabbit polynclonal antibody, dilution 1:750 
in 3% milk, sample cooking 70 ◦C 10-min), PDE8A (Santa Cruz 
Biotechnology sc-17,232, goat polynclonal antibody, dilution 1:500 in 
3% BSA, sample cooking 70 ◦C 10-min), EPAC2 (Cell signaling #4156, 
mouse monoclonal antibody, dilution 1:250 in 3% BSA, sample cooking 
55 ◦C 30-min), PIK3γ (kindly provided by Dr. Emilio Hirsch, mouse 
polyclonal antibody, dilution 1:100 in 3% BSA, 70 ◦C 10-min), GAPDH 
(HyTest #5G4 6C5, mouse monoclonal antibody, dilution 1:160,000 in 
5% milk). For quantification, band densitometry analysis was done 
using ImageJ software. 
2.5. Statistical analysis 
Results are expressed as mean ± SEM. Statistical significance was 
evaluated using a Student’s t-test and ANOVA followed by Tukey’s test 
was used for comparison of multiple effects. A difference was considered 
statistically significant when p < 0.05. 
3. Results 
Using RT-qPCR, we simultaneously evaluated the expression of 49 
target genes and normalized it to the appropriate reference genes [15]. 
In total, 113 human atrial appendage-tissue samples (Tables 1 and 2) 
from right and left atria controls or with distinct cardiovascular diseases 
were analyzed. Western Blot was used to confirm protein changes for 
specific genes in 37 samples. 
3.1. Validation of the control groups 
Working with human cardiac samples entails intrinsic subject het-
erogeneity. For instance, SR atrial appendage samples obtained from 
patients undergoing cardiac surgery due to cardiovascular diseases, 
which do not affect the atrium or the heart rhythm, were snap-frozen 
immediately after resection from the patient. In contrast, Ctl atrial 
appendage samples derived from donor hearts not suitable for 
Table 1 
Clinical characteristics of patients/samples used for gene expression experiments.  
Patients (n) SRnd SRd pAF cAF Ctl HF n = 9 
RAA, n = 8 RAA, n = 8 LAA, n = 5 RAA, n = 8 RAA, n = 8 LAA, n = 7 RAA-LAA, n = 8 RAA, n = 8 LAA, n = 8 
Female gender 3 (38%) 4 (50%) 2 (40%) 2 (25%) 3 (38%) 2 (29%) 3 (38%) 3 (38%) 3 (38%) 
Age (years) 69.5 ± 2.9# 69.8 ± 3.1# 64.4 ± 3.3# 76.0 ± 4.0# 74.3 ± 2.3# 71.6 ± 3.8# 44 ± 4.7 63.0 ± 3.4# 61.9 ± 3.7# 
Smoking 2 (25%) 2 (25%) 1 (20%) 1 (13%) 3 (38%) 2 (29%) N/A N/A N/A 
Hypertension 5 (62%) 4 (50%) 3 (60%) 4 (50%) 5 (62%) 4 (57%) 4 (50%) 8 (100%) 8 (100%) 
CAD 5 (62%) 3 (37%) 1 (20%) 2 (25%) 2 (25%) 1 (14%) 0 (0%) 0 (0%) 0 (0%) 
AVD/MVD 1 (13%) 4 (50%) 3 (60%) 3 (38%) 4 (50%) 4 (57%) 0 (0%) 0 (0%) 0 (0%) 
CAD + AVD/MVD 2 (25%) 1 (13%) 1 (20%) 3 (38%) 2 (25%) 2 (29%) 0 (0%) 0 (0%) 0 (0%) 
Transplantation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 8 (100%) 8 (100%) 8 (100%) 
LAD (mm) 39.2 ± 1.4 44.3 ± 0.9* 46.8 ± 0.6* 43.8 ± 2.7 46.0 ± 3.9* 53.0 ± 6.7* N/A N/A N/A 
LVEF (%) 61.4 ± 2.3 62.7 ± 2.0 49.4 ± 0.4 57.9 ± 2.6 62.8 ± 2.6 64.0 ± 5.2 N/A 25.5 ± 1.5* 29.5 ± 5.5* 
Digitalis 0 (0%) 0 (0%) 0 (0%) 1 (13%) 0 (0%) 1 (14%) N/A N/A N/A 
ACE inhibitors 3 (38%) 4 (50%) 4 (80%) 3 (38%) 4 (50%) 5 (71%) 4 (50%) N/A N/A 
AT1 blockers 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/A N/A N/A 
Beta-blockers 5 (63%) 4 (50%) 5 (100%) 4 (50%) 5 (63%) 5 (71%) N/A N/A N/A 
Ca2+-antagonists 0 (0%) 2 (25%) 0 (0%) 1 (13%) 3 (38%) 2 (29%) 0 (0%) N/A N/A 
Diuretics 1 (13%) 2 (25%) 3 (60%) 3 (38%) 5 (63%) 4 (57%) 4 (50%) N/A N/A 
Nitrates 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N/A N/A 
Statins 5 (63%) 2 (25%) 4 (50%) 2 (25%) 1 (13%) 2 (29%) 0 (0%) N/A N/A 
Amiodaron 0 (0%) 0 (0%) 0 (0%) 6 (75%) 2 (25%) 2 (29%) 0 (0%) N/A N/A 
Values are presented as mean ± SEM or number of patients (%). SRnd: Sinus Rhythm without atrium dilation; SRd: Sinus Rhythm with atrium dilation; pAF: 
Paroxysmal Atrial Fibrillation; cAF: Chronic Atrial Fibrillation; HF: Heart Failure; Ctl: Control donors; ACE: angiotensin-converting enzyme; AT: angiotensin receptor; 
AVD/MVD: aortic/mitral valve disease; CAD: coronary artery disease; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; N/A: not available. * indicates 
p < 0.05 vs. SRnd, # indicates p < 0.05 vs. Ctl. CAD, AVD/MVD, and CAD + AVD/MVD reflect the indications for cardiac surgery (bypass surgery, valve surgery or 
both). 
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transplantation due to logistical reasons were usually perfused with, and 
stored in, a cardioplegic solution, histidine-tryptophan-ketoglutarat 
Custodiol® solution. We first tested the possibility that differences 
might exist between the cardioplegia treated or not treated samples 
under such conditions. We found comparable expression values between 
SR and Ctl atrial groups (Supplemental Table 2). These results suggest 
that 1) cAMP-signaling cascade related genes are not affected by the 
content of this cardioplegic solution, and that 2) it is appropriate to use 
diseased (SR) samples as potential controls. 
3.2. Chamber-specific gene expression patterns in atria of the control 
donors human hearts 
All tested genes were expressed in the right and the left atrial ap-
pendages. Furthermore, most of the genes showed similar gene expres-
sion values in the two chambers in the Ctl and SR samples (Fig. 1). The 
only significant differences were observed in AC7 and PDE2A, which 
tended to a higher expression in the left atrium when comparing right 
and left atrial appendages from SR patients. Western blotting experi-
ments for PDE2A confirmed this tendency in protein expression. 
3.3. Gene expression changes in human atrial fibrillation 
Upregulation of the β-AR/cAMP pathway and increased phosphor-
ylation of key proteins in EC coupling are the hallmarks of AF. 
Accordingly, many genes involved into the β-AR/cAMP pathway are 
affected by AF (Fig. 2). Previous studies described gene expression 
changes in AF on PP1 [16] and BNP [17,18] and no change on IPP1, IPP2 
[19], PP2CA [16,19] and CaMKIID [20]. By using a validated set of 
reference genes [15], we found a downregulation of AC9, AKAP9, AKIP, 
PDE3A, PDE4B, IPP2 and PKACA when comparing right and left atrial 
appendages in SR versus AF (Fig. 2A). AKAP5 and Epac1 also showed a 
tendency to diminution (Supplemental Table 2). PDE8A, PI3Kγ and 
EPAC2 were upregulated (Fig. 2A), with Arrestin b2 and PDE1A showing 
a clear trend augmentation in AF (Supplemental Table 2). We confirmed 
the upregulation of PDE8A, PI3Kγ and EPAC2 at the protein level using 
immunoblots (Fig. 2B). In contrast, MRP4, MRP5, AC2, AC4, AC5, AC6, 
AC7, AKAP6, AKAP7, AKAP13, Arrestin b1, BNP, CaMKIID, PDE1C, 
PDE2A, PDE3B, PDE4A, PDE4D, PKIA, PKIB, PP1A, PP2CA, IPP1, PKACB, 
RIA, RIIA, RIIB, β1-AR, β2-AR, Gi1, Gi2, Gi3 and Gs showed similar gene- 
expression patterns in all groups. 
Interestingly, some genes appeared to be regulated in a chamber- 
specific manner. While BNP, PDE8A, PP2CA and EPAC2 expression 
increased in the RAA with pAF or cAF (Fig. 2C), PI3Kγ expression 
increased and MRP5 and PKIA expression decreased only in the LAA 
with AF (Fig. 2D). 
3.4. Atrial heart failure-related gene-expression patterns 
Although HF is extensively studied in the ventricle, less is known 
about whether and how HF affects the atria. Fig. 3A shows that HF 
strongly affects atrial cAMP-pathway gene expression. MRP4, MRP5, 
Arrestin b2, PDE4B, PDE4D and PKIB are downregulated, while AC2, 
AC5, AC6, AC9, AKAP9, AKIP, PDE1C, PDE3B, PKIA, PKIB, PP2CA, 
PKACA, PKACB, RIA, RIIB, EPAC1 and CaMKIID are upregulated when 
comparing right and left atrial appendages together in Ctl versus HF. 
Although MRP4, PKACB and PDE1C expression tends to change in 
both atrial appendages in HF compared to Ctl, MRP4 downregulation 
and PKACB upregulation seem to be more specific to the RAA (Fig. 3B), 
and PDE1C is upregulated particularly in the LAA (Fig. 3C). 
3.5. Gene-expression changes due to β-blocker treatment 
The above results suggest that genetic remodeling of cAMP pathway 
in AF and HF patients might contribute to the altered sympathetic 
regulation of atrial function observed in these patients. To explore this 
further, we examined whether treatment of patients with β-blockers had 
any impact on their gene expression level. For this, samples from all 
groups of patients (see Table 1) were separated according to the absence 
or presence of AF, the absence or presence of atrial dilation and the 
absence or presence of β-blockers in their medication. Only few alter-
ations in gene expression were found to be associated with β-blocker 
treatments (Fig. 4). Importantly, treatment of AF-patients with 
β-blockers did not seem to promote a reverse remodeling. 
4. Discussion 
The present study is to our knowledge the first to compare mRNA- 
expression pattern of cAMP-cascade related genes in right and left 
atrial appendages of control human heart tissues and in hearts with 
different pathologies. The results are summarized in Fig. 5. 
HF and AF are intrinsically associated with increased endogenous 
neurohormonal activation, which induces several changes in the heart 
and vascular system to maintain cardiovascular homeostasis. At the 
same time, chronic neurohormonal activation is known to be one of the 
most important mechanisms underlying pathological remodeling and 
promoting changes in gene expression of several signaling pathways. 
Table 2 
Clinical characteristics of patients/samples used for protein expression 
experiments.  
Patients (n) SRnd SR pAF cAF 
RAA, 
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Values are presented as mean ± SEM or number of patients (%). SRnd: Sinus 
Rhythm without atrium dilation; SRd: Sinus Rhythm with atrium dilation; pAF: 
Paroxysmal Atrial Fibrillation; cAF: Chronic Atrial Fibrillation; HF: Heart Fail-
ure; Ctl: Control donors; ACE: angiotensin-converting enzyme; AT: angiotensin 
receptor; AVD/MVD: aortic/mitral valve disease; CAD: coronary artery disease; 
LAD, left atrial diameter; LVEF, left ventricular ejection fraction; N/A: not 
available. * indicates p < 0.05 vs. SRnd. CAD, AVD/MVD, and CAD + AVD/MVD 
reflect the indications for cardiac surgery (bypass surgery, valve surgery or 
both). 
A. Garnier et al.                                                                                                                                                                                                                                 
Journal of Molecular and Cellular Cardiology 155 (2021) 10–20
14
While changes occurring at the level of β-AR [21–23] have been 
extensively studied, only a few studies focussed on gene expression 
changes in the cAMP pathway. 
In contrast to previous work in ventricular samples describing gene 
changes due to exposure to cardioplegic solutions [24], we found similar 
expression levels between SR patients and donor Ctl individuals. This 
suggests that gene expression is less sensitive to cardioplegic solution in 
the atria than in the ventricles. However, many studies do not specify the 
kind of cardioplegic solution used. One major limitation of studies using 
human is the selection of appropriate controls. Atrial appendage tissue 
from patients being in sinus rhythm at time of tissue collection is 
frequently used as control group for studies dealing with AF or HF 
[25,26]. Our results suggest that atrial appendage samples from SR 
patients match those obtained from donor Ctl individuals, validating the 
use of atrial samples from SR patients as putative controls. This is 
important considering the very limited availability of atria from healthy 
individuals. Also, the absence of differences between non dilated and 
dilated SR in our set of genes made possible to combine these two groups 
as controls versus different pathologies. However, this may not neces-
sarily apply to other genes outside the cAMP-pathway. 
We found that the right and left atrial appendages in control hearts 
had similar gene expression values for all studied genes with the 
exception of AC7 and PDE2A, which showed particularly higher abun-
dance in left atria. However, β1-AR and β2-AR expression and density 
were previously found to be unchanged in AF [21,27] but, opposite to 
our results, higher in left versus right atrium [22]. Although similar gene 
expression profile between RAA and LAA was already described [14], it 
is important to note that PDE4, AKAP7, IPP1, AC2 and AC5 showed 
highly-variable expression patterns. Even if human samples are difficult 
to obtain, using low number of samples, especially in studies involving 
highly variable genes, could lead to erroneous conclusions. 
Despite the enormous variability in gene-expression profiles among 
specific pathologies, several distinguishable patterns could be identified. 
Expression of AC4, AC7, AKAP5, AKAP6, AKAP7, AKAP13, Arrestin b1, 
PDE1A, PDE2A, PDE4A, PP1A, IPP1, RIIA, β1-AR, β2-AR, Gi1, Gi2, Gi3 
and Gs remain unaltered during pathological remodeling in both atrial 
appendages. MRP5, PDE4B and PP2CA by contrast have similar 
expression changes in both pathologies. Expression of AC9, AKAP9, 
AKIP, PKIA and PKACA also change in all pathologies but in opposite 
direction: their expression increases in HF but is reduced in AF. The 
different PDE isoforms appeared regulated in a pathology-specific 
manner. For instance, PDE3A and PDE8A expression was modified in 
AF, but PDE1C, PDE3B and PDE4D expression was modified in HF. 
PDE8A expression increased in AF together with EPAC2 and PI3Kγ but 
not CaMKIID. On the other hand, EPAC1 and CaMKIID gene expression 
was upregulated in HF, together with AC2, AC6, AC5, RIA, RIIB and 
PKACB while MRP4, Arrestin b2 and PKIB gene expression was 
downregulated. 
We already reported reduced PDE4 and total PDE (IBMX-inhibited 
PDEs) activity in AF [25]. Here we confirm that PDE4B is downregulated 
in AF at the gene-expression level. Furthermore, PDE3A, one of the 
major isoforms in controlling cAMP-hydrolytic activity in human atria, 
is also downregulated in AF. Of note, the IBMX-insensitive PDE8A was 
upregulated in AF, particularly in the RAA. 
Fig. 1. Plot showing an overview of the results on the gene expression values for the different phosphodiesterases (PDEs, A), phosphatases (PPs, B) adenylyl cyclases 
(ACs, C) and A-kinases-anchoring proteins (AKAPs, D) within the non-cardiac disease atrial cavities (LAA: dilated and non-dilated left atrial appendages, n = 13; RAA: 
dilated and non-dilated right atrial appendages, n = 16). Separated small graphs in A and C panels show the only significant differences in gene expression between 
the samples from right and left non-cardiac disease atrial appendages (LAA SR: left atria, n = 5; RAA SRnd: non-dilated right atria, n = 8) as well as its corresponding 
protein expression (LAA SR n = 4, RAA SRnd n = 4). Right chambers values are indicated in blue, left chambers values are indicated in red. * indicates p ≤ 0.05 versus 
LAA in tissue from patients in sinus rhythm without atrial dilation (SRnd). (For interpretation of the references to colour in this figure legend, the reader is referred to 
the web version of this article.) 
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No change in PDE1A as well as an increase in PDE1C was observed in 
HF. Although PDE2 was previously found to be upregulated in the 
ventricles of HF patients [28], we found it stable in both atrial ap-
pendages and all pathologies. The results about expression levels of 
phosphatases are inconsistent. PP1A mRNA levels were previously found 
to be unchanged in AF [19], in agreement with our results, but also 
downregulated in another study [16]. Both IPP1 and IPP2 were found to 
be unchanged in AF [19], in agreement with our results. However, 
PP2CA levels were reported to be unaltered in AF [16], while we found 
an increased expression in cAF versus SRd. Similar discrepancies exist for 
PP1A [29,30], which we found unaltered. Several factors can be 
responsible for such large variability among studies: intrinsic genetic 
differences among patients, underlying pathology or state of the pa-
thology, medical treatments, age or sex differences. Also, various HF 
models and underlying aetiologies display different mRNA expression 
profiles [31]. Variability may also be caused by the use of a single and/ 
or inappropriate reference gene which could change the conclusions 
[15]. One example is MRP5. The multidrug resistant protein 4 (MRP4) 
and 5 (MRP5) act as cyclic nucleotides efflux pump regulating cytosolic 
cAMP and cGMP levels, respectively. MRP5 gene expression was pre-
viously found to be downregulated in atria compared to ventricle and 
upregulated in ischemic cardiomyopathy [32]. Unfortunately, this study 
used β-actin as housekeeping gene, which was found to be one of the 
most variable genes in human heart samples [15]. Our results based on 
the use of a validated set of 5 reference genes [15] show reduced MRP4 
and MRP5 gene expression levels in HF. By contrast, only MRP5 
expression was reduced in AF, yet only in the left atrial appendage. 
Although some reports have evidenced the functional role of MRP4 in 
ventricular myocytes function [33], to date, no heart disease or atrial 
myocyte dysfunction has been linked to altered MRP4 gene expression. 
EPAC shows a distinctive expression pattern, with very high levels of 
EPAC1 in HF and a tendency for downregulation in AF, while EPAC2 
shows a strongly increased expression. On the other hand, although 
some studies found an increased protein expression or activity of 
CaMKIIδ in cAF [26], we and others [34] found no change in its gene 
expression level or even a tendency for a decrease. By contrast, we found 
an increased expression of CaMKIID in the atrial appendages of patients 
with HF. 
Of particular interest is the increased expression of PI3Kγ in AF. 
PI3Kγ regulates PDE3 and PDE4 activity in mouse ventricle [35] and 
acts as a PKA-anchoring protein for PDE3B, enhancing its activity [36]. 
Indeed, PI3Kγ links β2-AR signaling to PDE4A, PDE4B and PDE3A, 
Fig. 2. Relative quantification of gene expression in atrial appendage samples from patients in sinus rhythm (SR) or with atrial fibrillation (AF). (A, C, D) Plot of the 
mean and individual expression values only for the genes whose expression levels were significantly different (p ≤ 0.05) between SR (n = 13) and AF (n = 15) in both 
right and left atrial appendage samples (AA); or between right atrial appendage (RAA) samples from SR patients without atrial dilation (SRnd, n = 8), SR patients 
with atrial dilation (SRd, n = 8), patients with paroxysmal AF (pAF, n = 8) and patients with persistent-chronic AF (cAF, n = 8) (C); or between left atrial appendage 
samples (LAA) from SRnd (n = 5) and cAF (n = 7) patients (D). The data are normalized to the validated set of reference genes. (B) Representative immunoblots of 
EPAC2 and PDE8A in right atrial samples and of PI3Kγ in left atrial samples from patients in SR (n = 8, 6 and 11, respectively) and AF (n = 6, 6 and 11, respectively). 
The GAPDH levels were used as internal control. Values from SR patients are indicated in black, values from AF patients in red.* indicates p ≤ 0.05 versus SR. Panels B 
and C show the genes with chamber-specific differences. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version 
of this article.) 
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limiting β2-AR–induced cAMP elevation and PKA-dependent phosphor-
ylation of LTCC and PLB, preventing spontaneous arrhythmogenic Ca2+
releases in ventricles [35]. Our results demonstrating PI3Kγupregulation 
suggest a potential role of this molecule in the AF-related remodeling of 
LTCCs. On the other hand, PI3Kγ upregulation may be a compensatory 
mechanism in order to limit arrhythmogenic Ca2+ abnormalities linked 
to AF, the reduction of PDE3A and PDE4B expression observed here or 
the downregulation of PKACA expression. 
Unexpectedly, BNP but not ANP was upregulated in pAF samples 
from RAA. Previous studies already reported an increase of BNP levels in 
AF [18] or ANP levels in HF [37]. Importantly, and in line with other 
authors [24], we found a highly variable natriuretic peptides (NP) 
expression, especially in donor Ctl individuals, probably because some 
non-failing hearts might have some pathology that made them unsuit-
able for transplantation and/or subjected to strong medication cocktails 
until organs extraction. On the other hand, it is well known that plasma 
levels of NP change quickly depending on the clinical conditions, in-
terventions and treatments of the patient but the relationship between 
transcriptional and plasma level changes in NP expression and its 
different metabolites is not clear. 
AKAP9 binds to potassium channels (KCNQ1) and was shown to be 
linked to long-QT syndrome [38] so it was expected to change its 
expression in pathological conditions. While AKAP9 expression 
increased in HF in both atrial appendages, it is decreased in cAF. 
Although AKAP5 binds to LTCC [39], this anchoring protein seems to be 
unchanged in AF. AKAP13 was reported to be upregulated during hy-
pertrophy [40] as well as in the transverse aortic constriction mouse 
model [41], but its expression was unchanged between our pathological 
groups or between right and left atrial appendages, as previously shown 
[42]. It was also shown that AKAP6 might induce myocyte hypertrophy 
by regulating calcineurin [43] although we found no change in its 
expression. Our results on AKAP6 are in agreement with the study of 
Zakhary and colleagues [44] pointing towards a decreased PKA-RII 
autophosphorylation as a reason for limiting AKAP/PKA-RII interac-
tion and affecting PKA targets. But these authors also described 
decreased PKA-RII and PKA-RI protein levels in human samples from 
patients with dilated cardiomyopathy. No change in RIIA and the 
PKACA subunit, as well as increased RIA expression in HF was also 
previously reported [45]. We found PKIA, PKACA, RIA, RIIB and PKACB 
upregulation and PKIB downregulation in HF, and no change in gene 
expression for RIIA. 
In agreement with previous studies [21,22,46–48], no expression 
changes were observed in β1-AR, β2-AR, Gs, Gi1, Gi2 and Gi3 genes 
between chambers or in pathologies (Supplemental Table 2). However, 
β1-AR gene expression showed a tendency to decrease in atrial 
appendage samples from HF patients compared to Ctl. Furthermore, 
separation of the patients according to the absence or presence of 
β-adrenergic receptor blocker treatment revealed very few alterations in 
Fig. 3. Relative quantification of gene expression in atrial appendage samples from control donor patients (Ctl) or with end-stage heart failure (HF). (A–C) Plot of the 
mean and individual expression values only for the genes whose expression levels were significantly different (p ≤ 0.05) between atrial appendage samples (AA) from 
Ctl (n = 16) and HF (n = 16) patients (A); between right atrial appendage (RAA) samples from Ctl (n = 8) and HF (n = 8) patients (B); or between left atrial 
appendage samples (LAA) from Ctl (n = 8) and HF (n = 8) patients (C). The data are normalized to the validated set of reference genes. Values from Ctl patients are 
indicated in black, values from HF patients are indicated in red. Panels B and C show the genes with chamber-specific differences. (For interpretation of the references 
to colour in this figure legend, the reader is referred to the web version of this article.) 
A. Garnier et al.                                                                                                                                                                                                                                 
Journal of Molecular and Cellular Cardiology 155 (2021) 10–20
17
the expression of genes linked to cAMP pathway and, by comparing the 
effects of β-blocker treatment and the effects of AF on gene expression, 
none of those changes seemed associated to a reverse remodeling. 
5. Limitations 
Despite the statistically significant differences in gene expression 
between specific groups, the number of tissue samples for some com-
parisons were relatively limited (LAA-SR n = 5). In addition, only a few 
right and left atrial appendage samples were paired. On the other hand, 
patients of the Ctl group were younger than the other groups of patients. 
Thus, age could be a confounding factor on the interpretation of the 
data, especially when comparing Ctl and HF. Furthermore, some infor-
mation regarding medication of the Ctl and HF groups is missing making 
it not possible to check if gene expression could change because of the 
treatment of the patients in these groups. No comorbidities promoted 
differences that could change the results of the study. 
Due to better accessibility we were able to use tissue only from right 
and left atrial appendages. Despite evidence for a potential role of these 
regions for AF pathophysiology, the atria are highly heterogeneous and 
other regions (e.g. left posterior free wall or the pulmonary veins) could 
be considered more important in the evolution and maintenance of AF 
[49]; these issues should be considered when translating our results to 
other atrial regions and interpreting their potentials roles in promoting 
AF or HF. In addition, experiments were performed in human whole 
tissue samples. Thus, the results are based not only on cardiomyocyte 
mRNA content, but also include many other cell types like fibroblasts, 
endothelial and immune cells. A nuclear but not whole cell 
transcriptional analysis from a recent single-cell resolution study 
revealed that ADCY4, ADCY7, ADCY9, AKAP9, ARRB1, ARRB2, 
PRKAR2B, RAPGEF3, RAPGEF4, PDE1A, PDE1C, PDE2A, PDE3B, 
PDE4B and PDE8A are also relatively highly expressed in endothelial, 
fibroblast, macrophages, pericytes and/or neuronal cells [14]. So, it is 
important to keep this in mind even if cardiomyocytes account for the 
majority of heart mass and are the more common cell type in our sam-
ples without fat. Nevertheless, cell-type heterogeneity does not change 
the main conclusion of our results and the possible functional conse-
quences of the detected differences. 
6. Conclusions 
In the present manuscript, we studied the remodeling of the cAMP- 
signaling cascade induced by different pathologies in human atrial ap-
pendages. Our data indicate that cAMP-signaling cascade related genes 
of atrial SR samples are not affected by cardioplegic solution content, 
providing a potential alternative for control donor individuals and 
serving as appropriate controls. Our data also reveal that in the control 
hearts, only AC7 and PDE2A expression is different between atrial 
chambers, being higher in the left versus right atrial appendages. 
Furthermore, many genes in the cAMP pathway are affected in AF and 
HF, but only few changes were also chamber-specific. Of particular in-
terest is the increased expression of PI3Kγ, EPAC2 and PDE8A in AF. By 
comparing mRNA-expression patterns of the cAMP-signaling cascade 
related genes in RAA and LAA of human hearts and across different 
pathologies, our study may help identifying new genes of interest as 
potential therapeutic targets or clinical biomarkers for these 
Fig. 4. Relative gene expression changes in response to β-blocker treatment. (A–C) Plot of the mean and individual expression values only for the genes whose 
expression levels were significantly different (p ≤ 0.05) between patients with (bb) or without β-blockers treatment (no-bb): A in right atrial appendage samples 
(RAA) from patients with persistent atrial fibrillation (cAF); B in left atrial appendage samples (LAA) from patients with atrial fibrillation (AF); C in RA samples from 
patients in sinus rhythm without atrial dilation (SRnd); and D in RAA samples from patients in sinus rhythm with atrial dilation (SRd). Values from SR patients are 
indicated in black, values from AF patients in red. 
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Fig 5. Graphical summary of the differences in gene expression between control right and left atrial appendages (A) or the differences within each atrial chamber 
induced by atrial fibrillation (B) or heart failure (C). Genes that are downregulated are indicated in red, and those upregulated in green. (D) Schematic representation 
of the changes in gene expression during atrial fibrillation and heart failure in human atrial myocytes. Only the genes involved in cAMP-signaling cascade studied 
here are represented by their respective transcribed proteins, enzymes or receptors with respect to their role in regulating excitation-contraction coupling. Up and 
down arrows indicate up- or downregulation in atrial fibrillation (in red) or heart failure (in green). (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
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